A Prognostic Model Based on NSUN3 Was Established to Evaluate the Prognosis and Response to Immunotherapy in Liver Hepatocellular Carcinoma

Figure 6

Risk scores from NCGs-related model predict LIHC response to immunotherapy. (a) Correlation of NCGs risk score with multiple immune checkpoints. (b) Differences in expression of multiple immune checkpoints in the high- and low-risk groups. (c) In the case of CTLA4 negative but PD1 positive, the high-risk group had lower IPS. (d) In the case of CTLA4 positive but PD1 negative, the high-risk group had lower IPS. (e) In the case of CTLA4 and PD1 negative, the high-risk group had lower IPS. (f) Low-risk patients have more pronounced immune dysfunction. (g) High-risk patients have a stronger tendency to immune exclusion. (h) Low-risk patients have lower TIDE scores.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)